Sociedad Hispanoamericana de Hernia

Acceso gestor editorial



Revista Sociedad Hispanoamericana de Hernia H0086
Resumen| PDF

Revisión

Lesiones ocupantes de espacio no herniarias de la pared abdominal desde el prisma del oncólogo médico. El reto del abordaje de los tumores raros en la oncología del siglo xxi


Logo Descargas   Número de descargas: 13403      Logo Visitas   Número de visitas: 562      Citas   Citas: 0

Compártelo:


Las lesiones ocupantes de espacio que podemos encontrar en la pared abdominal, aunque poco frecuentes, pueden tener etiologías muy diferentes. En esta revisión abordaremos el diagnóstico clínico y las opciones terapéuticas de las lesiones ocupantes de espacio más frecuentes en la pared abdominal desde el punto de vista del oncólogo médico, y por tanto, nos limitaremos a los tumores que pueden asentar en la pared abdominal, tanto primarios como metastásicos.

Palabras Clave : Tumores de la pared abdominal. Quimioterapia.


Logo Descargas   Descargar PDF   

Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP,Kunkler I, et al. RARECARE working group. Rare cancers arenot so rare: the rare cancer burden in Europe. Eur J Cancer.2011;47:2493–511.
DOI: 10.1016/j.ejca.2011.08.008
Bashir U, Moskovic E, Strauss D, Hayes A, Thway K, Pope R,et al. Soft-tissue masses in abdominal wall. Clin Radiol.2014;69:e422–31.
DOI: 10.1016/j.crad.2014.06.006
Bastiaannet E, Groen H, Jager PL, Cobben DC, van der GraafWT, Vaalburg W, et al. The value of FDG-PET in the detection,grading and response to therapy of soft tissue and bonesarcomas: A systematic review and meta-analysis. CancerTreat Rev. 2004;30:83–101.
Rampone B, Pedrazzani C, Marrelli D, Pinto E, Roviello F.Updates on abdominal desmoids tumors. World JGastroenterol. 2007;13:5985–8.
DOI: 10.3748/wjg.v13.45.5985
Overhaus M, Decker P, Fischer HP, Textor HJ, Hirner A, ATDesmoid tumors of the abdominal wall: A case report. World Jof Surg Oncol. 2003;1:11.
DOI: 10.1186/1477-7819-1-11
Galeotti F, Facci E, Bianchini E. Desmoid tumor involving theabdominal rectus muscle: Report of a case. Hernia.2006;10:278–81.
DOI: 10.1007/s10029-006-0075-5
Stojadinovic A, Karpoff HM, Leung DH, Antonescu CR,Brennan MF, Lewis JJ. Soft tissue tumors of the abdominalwall analysis of disease patterns and treatment. Arch Surg.2001;136:70–9.
DOI: 10.1001/archsurg.136.1.70
Dômont D, Salas S, Lacroix L, Brouste V, Saulnier P, Terrier P,et al. High frequency of beta-catenin heterpozygousmutations in extra-abdominal fibromatosis; a potentialmolecular tool for disease management. Br J Cancer.2010;102:1032–6.
DOI: 10.1038/sj.bjc.6605557
Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissuesarcomas in adults. N Engl J Med. 2005;353:701–11.
DOI: 10.1056/NEJMra041866
Gluck I, Griffith KA, Biermann JK, Feng FY, Lucas DR, Ben-JosefE. Role of radiotherapy in the management of desmoidtumors. Int J Radiat Oncol Biol Phys. 2011;80:787–92.
DOI: 10.1016/j.ijrobp.2010.02.053
Chugh R, Wathen JW, Patel SR, Maki RG, Meyers PA, SchuetzeSM, et al. Efficacy of imatinib in aggressive fibromatosis;Results of phase II multicentre Sarcoma Alliance for Researchthrough Collaboration (SARC) trial. Clin Cancer Res.2010;16:4884–91.
DOI: 10.1158/1078-0432.CCR-10-1177
Pennel N, Le Cesne A, Bui BN, Perol D, Brain EG, Ray-CoquardI, et al. Imatinib for progressive and recurrent aggressivefibromatosis (desmoid tumors); an FNCLCC/French SarcomaGroup phase II trial with a long-term follow-up. Ann Oncol.2011;22:452–7.
DOI: 10.1093/annonc/mdq341
Desurmont T, Lefevre JH, Shields C, Colas C, Tiret E, Parc Y.Desmoid tumour in familial adenomatous polyposis patients:Responses a treatment. Fam Cancer. 2015;14:31–9.
DOI: 10.1007/s10689-014-9760-1
Casali PG, Blay JY. Soft tissue sarcomas: ESMO ClinicalPractice Guidelines for diagnosis; treatment andfollowing-up. Ann Oncol. 2010;21:198–203.
DOI: 10.1093/annonc/mdq209
Rubin BP, Cooper K, Fletcher CD, Folpe AL, Gannon FH, HuntJL, et al. Protocol for the examination of specimens frompatients with tumors of soft tissue. Arch Pathol Lab Med.2010;134:31–9.
DOI: 10.5858/134.4.e31
Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG,Woodruff JM, et al. Dermatofibrosarcoma protuberans: Aclinicopathologic analysis of patients treated and followed ata single institution. Cancer. 2000;88:2711–20.
DOI: 10.1002/1097-0142(20000615)88:12<2711::AID-CNCR9>3.0.CO;2-M
Pedeutour F, Simon MP, Minoletti F., Barcelo G,Terrier-Lacombe MJ, Combemale P, et al. Translocationt(17;22)-(q22;q13) in dermatofibrosarcoma protuberans: A newtumor-associated chromosome rearrangement. Cyto-genetCell Genet. 1996;72:171–4.
DOI: 10.1159/000134178
McArthur GA, Demetri GD, van Oosterom A, Heinrich MC,Debiec-Rychter M, Corless CL, et al. Molecular and clinicalanalysis of locally advanced dermatofibrosarcomaprotuberans treated with imatinib: Imatinib TargetExploration Consortium Study B2225. J Clin Oncol.2005;23:866–73.
DOI: 10.1200/JCO.2005.07.088
Molinari L, Galimberti G. Dermatofibrosarcoma protuberans.Mohs micrographic surgery vs. conventional surgery. Piel(Barc). 2011;26, http://dx.doi.org/10.1016/j.piel.2011.04.010.
DOI: 10.1016/j.piel.2011.04.010
Spinalle AJ, A’Hern R, Judson IR, Fisher C, Thomas JM.Synovial sarcoma: A clinicopathologic, staging, andprognostic assessment. J Clin Oncol. 2000;18:1794–803.
Sandberg AA, Bridge JA. Updates on cynetics amd moleculargenetics of bone and soft tissues tumors. Synovial sarcoma.Cancer Genet Cytogenet. 2002;133:1–23.
Van de Rjn M, Barr FG, Xiong QB, Hedges M, Shipley J, FisherC. Poorly differeciated sinovial sarcoma: An analisis ofclinical, pathologic and molecular genetic features. Am J SurgPathol. 1999;23:106–12.
DOI: 10.1097/00000478-199901000-00012
Scurr M. Histology-driven chemotherapy in soft tissuesarcomas. Curr Treat Options Oncol. 2011;12:32–45.
DOI: 10.1007/s11864-011-0140-x
D’Adamo DR. Appraisingthe current role of chemotherapy forthe treatment of sarcoma. Semin Oncol. 2011;38:19–29.
DOI: 10.1053/j.seminoncol.2011.09.004
Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C,Judson I. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma:Retrospective analysis and identification of prognostic factorsin 488 patients. Cancer. 2008;112:1585–91.
DOI: 10.1002/cncr.23332
Le Cesne A, Crestas S, Maki RG, Blay JY, Verweij J, Poveda A,et al. A retrospective analysis of antitumour activity withtrabectidin in translocation related sarcomas. Eur J Cancer.2012;48:3036–44.
DOI: 10.1016/j.ejca.2012.05.012
San Filippo R, Dileo P, Blay JY. Trabectidin in advancedpre-treated synovial sarcoma; a retrospective analysis of 61patients from four European institutions and from the Italianrare cancer netwok. CTO 17th Annual Meeting. Praga2012:14-17 noviembre.
Blay JY, Italiano A, Ray-Coquard I, Le Cesne A, Duffaud F, RiosM, et al. Long term outcome and effect of maintenancetherapy in patients with advanced sarcoma treated withtrabectidin: An analysis of 181 patients of the French ATUcompassionate use program. BMC Cancer. 2013;13:64.
DOI: 10.1186/1471-2407-13-64
Ploner F, Lamm W, Schur S, Eisterer W, Kühr T, Lindorfer A,et al. The Australian experience with trabectidin innon-selected patients with metastatic soft-tissue sarcoma. JCancer Res Clin Oncol. 2013;139:1337–42.
DOI: 10.1007/s00432-013-1447-8
Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG. A14-year retrospective review of angiosarcoma: Clinicalcharacteristics, prognostic factors and treatment outcomeswith surgery and chemotherapy. Cancer J. 2005;11:241–7.
DOI: 10.1097/00130404-200505000-00011
Fayette J, Martin E, Piperno-Neumann S, Le Cesne A, Robert C,Bonvalot S, et al. Angiosarcomas, a heterogeneous group ofsarcomas with specific behavior depending of primary site: Aretrospective study of 161 cases. Ann Oncol. 2007;18:2030–6.
DOI: 10.1093/annonc/mdm381
Valverde C, Nú˜nez I, Romagosa C, Morales R, Mulet N, SuárezC, et al. Estrategia de tratamiento de los sarcomas pocofrecuentes de origen vascular. Uncommon Oncology.2012;1:5–15.
Penel N, Italiano A, Ray-Coquard I., Chaigneau L, DelcambreC, Robin YM, et al. Mestastatic angiosarcomas: Doxorubicinbased regimens, weekly paclitaxel and metastatectomysignificantly improve the outcome. Ann Oncol.2012;23:517–23.
DOI: 10.1093/annonc/mdr138
Italiano A, Cioffi A, Penel N, Levra MG, Delcambre C,Kalbacher E, et al. Comparasion of doxorubicin and weeklypaclitaxel efficacy in metastatic angiosarcomas. Cancer.2012;118:3330–6.
DOI: 10.1002/cncr.26599
García-del-Muro X, López-Pousa A, Maurel J, Martín J,Martínez-Trufero J, Casado A, et al. Spanish Group forResearch on Sarcomas. Randomized phase II studycomparing gemcitabine plus dacarbazine versus dacarbazinealone in patients with previously treated soft tissue sarcoma:A Spanish Group for Research on Sarcomas study. J ClinOncol. 2011;29:2528–33.
DOI: 10.1200/JCO.2010.33.6107
Stacchiotti S, Palassini E, Sanfilippo R, Vincenzi B, Arena MG,Bochicchio AM, et al. Gemcitabine in advanced angiosarcoma:A retrospective case series analysis from the Italian RareCancer Network. Ann Oncol. 2012;23:501–8.
DOI: 10.1093/annonc/mdr066
George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT,Akhurst T, et al. Multicenter phase II trial of sunitinib in thetreatment of nongastrointestinal stromal tumor sarcomas. JClin Oncol. 2009;27:3154–60.
DOI: 10.1200/JCO.2008.20.9890
Dei Tos AP. Liposarcoma new entities and evolving concepts.Ann Diagn Pathol. 2000;4:252–66.
DOI: 10.1053/adpa.2000.8133
Weiss WS, Goldblum JR. Enzinger and Weiss’s soft tissuetumours. 4.aed St. Louis: Mosby; 2001. p. 271–694.
Linehan DC, Lewis JJ, Leung D, Brennan MF. Influence ofbiologic factors and anatomic situ in completerly resectedliposarcoma. J Clin Oncol. 2000;18:1637–43.
DOI: 10.1200/JCO.2000.18.8.1637
Carter N, Keam S. Trabectedin. A review of its use inmanagement of soft tissue sarcoma. Drugs. 2007;67:2257–76.
DOI: 10.2165/00003495-200767150-00009
Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C,et al. Phase II study of ecteinascidin-743 in advancedpretreated soft tissue sarcoma patients. J Clin Oncol.2004;22:890–9.
DOI: 10.1200/JCO.2004.05.210
Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, HarmonD, Ryan DP, et al. Phase II and pharmacokinetic study ofecteinascidin-743 in patientes with progressive sarcomas ofsoft tissue refractory to chemotherapy. J Clin Oncol.2004;22:1480–90.
DOI: 10.1200/JCO.2004.02.098
Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, BlayJY, et al. Efficacy and safety of trabectidin in patients withadvanced or metastatic liposarcoma or leiomyosarcoma afterfailure of prior anthracyclines and ifosfamide; results ofrandomized phase II study of two different schedules. J ClinOncol. 2009;27:4188–96.
DOI: 10.1200/JCO.2008.21.0088
Adjuvant chemotherapy for localised resectable soft-tissuesarcoma of adults: Meta-analysis of individual data. Sarcomameta-analysis collaboration. Lancet. 1997;350:1647–54.
DOI: 10.1016/S0140-6736(97)08165-8
Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A,Ghert M. A systematic meta-analysis of randomizedcontrolled trials of adjuvant chemotherapy for localizedresectable soft-tissue sarcoma. Cancer. 2008;113:573–81.
DOI: 10.1002/cncr.23592
Gortzak E, Azzarelli A, Buesa J, Bramwell VH, van Coevorden F,van Geel AN, et al. A randomised phase II study onneoadjuvant chemotherapy for highrisk adult soft-tissuesarcoma. Eur J Cancer. 2001;37:1096–103.
DOI: 10.1016/S0959-8049(01)00083-1
Pisters PW, Ballo MT, Fenstermacher MJ, Feig BW, Hunt KK,Raymond KA, et al. Phase I trial of preoperative concurrentdoxorubicin and radiation therapy, surgical resection, andintraoperative electron-beam radiation therapy for patientswith localized retroperitoneal sarcoma. J Clin Oncol.2003;21:3092–7.
DOI: 10.1200/JCO.2003.01.143
Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, BlumRH, et al. Phase II study of neoadjuvant chemotherapy andradiation therapy in the management of high-risk,high-grade, soft tissue sarcomas of the extremities and bodywall: Radiation Therapy Oncology GroupTrial 9514. J ClinOncol. 2006;24:619–25.
DOI: 10.1200/JCO.2005.02.5577
Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, FrytakS, et al. Randomized comparison of doxorubicinalone versusifosfamide plus doxorubicin or mitomycin, doxorubicin, andcisplatin against advanced soft tissue sarcomas. J Clin Oncol.1993;11:1269–75.
DOI: 10.1200/JCO.1993.11.7.1269
Buesa JM, López-Pousa A, Martín J, Antón A, García del Muro J,Bellmunt J, et al. Phase II trial of first-line highdose ifosfamidein advanced soft tissue sarcomas of the adult: A study of theSpanish Group for Research on Sarcomas (GEIS). Ann Oncol.1998;9:871–6.
DOI: 10.1023/A:1008474802882
Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, SomersR, et al. Doxorubicin versus CYVADIC versus doxorubicin plusifosfamide in first-line treatment of advanced soft tissuesarcomas: A randomized study of the European Organizationfor Research and Treatment of Cancer Soft Tissue and BoneSarcoma Group. J Clin Oncol. 1995;13:1537–45.
DOI: 10.1200/JCO.1995.13.7.1537
Vijayasekar C, Noormohamed S, Cheetham MJ. Laterecurrence of large peristomal metastasis followingabdomino-perineal resection of rectal cancer. World J of SurgOncol. 2008;6:96.
Funahashi K, Ushigome M, Kaneko H. A role of18F-fluorodeoxyglucose positron emission/computedtomography in a strategy for abdominal wall metastasis ofcolorectal mucinous adenocarcinoma developed afterlaparoscopic surgery. World J Surg Oncol. 2011;9:28.
DOI: 10.1186/1477-7819-9-28

Revisión: Tratamiento quirúrgico de los tumores de la pared abdominal

Publicado: 2021-02-03 / http://dx.doi.org/

Artículos más populares

Original: Creación del espacio retrorrectal en hernioplastia totalmente extraperitoneal con la técnica de varilla: una forma costo-efectiva de sustituir el trocar con balón disector

Introducción: La técnica eTEP es una técnica noved...

Publicado: 2020-07-24

Caso Clínico: Leiomiosarcoma cutáneo en pared abdominal, una entidad poco frecuente para el cirujano general

El leiomiosarcoma cutáneo primario es una neoplasi...

Publicado: 2020-06-18

Caso Clínico: Perforación por hueso de pollo en asa intestinal incarcerada de hernia incisional

Introducción: La ingesta de cuerpos extraños suele...

Publicado: 2020-06-05

Editado en Madrid por:
Diseño y Desarrollo web Im3diA comunicación

Una cookie o galleta informática es un pequeño archivo de información que se guarda en su navegador cada vez que visita nuestra página web. La utilidad de las cookies es guardar el historial de su actividad en nuestra página web, de manera que, cuando la visite nuevamente, ésta pueda identificarle y configurar el contenido de la misma en base a sus hábitos de navegación, identidad y preferencias. Las cookies pueden ser aceptadas, rechazadas, bloqueadas y borradas, según desee. Ello podrá hacerlo mediante las opciones disponibles en la presente ventana o a través de la configuración de su navegador, según el caso. En caso de que rechace las cookies no podremos asegurarle el correcto funcionamiento de las distintas funcionalidades de nuestra página web. Más información en el apartado “POLÍTICA DE COOKIES” de nuestra página web.